COMBACTE-MAGNET stands for Combatting bacterial resistance in Europe – Molecules against Gram-negative infections. The project focuses on the most vulnerable category of patients: those who are critically ill and being treated in intensive-care units. Gram-negative bacteria cause most ICU-associated infections. This project aims to find better options to deal with that threat.
The COMBACTE-MAGNET consortium brings together researchers from five pharmaceutical companies. And over thirty leading academic medical centers from ten European countries. Together we will increase our understanding of the needs of patients and doctors in intensive-care units across Europe. This knowledge will be used to advance the development of well-targeted, life-saving treatments.
COMBACTE-MAGNET aims to:
- provide ground-breaking multinational phase I, II, and III studies targeting multidrug-resistant Gram-negative bacteria;
- analyze data about current microbial threats, treatment and drug resistance patterns in European countries where ICU patients are most at risk;
- gather information on biological markers of Pseudomonas aeruginosa infections;
- create mathematical models of the infection’s effects;
- provide a better understanding of why various patients may respond differently to infections;
- provide researchers with knowledge to design more efficient and effective clinical trials of new molecules, accelerating the drug-development process enormously.
EPI-Net: a network of epidemiological data and expertise
The project brings together top-tier researchers from five pharmaceutical companies and more than 30 leading academic medical centers from 10 European countries. They combine their knowledge and capabilities to deliver the aforementioned aims. As part of the solution, they created EPI-Net, a European network of epidemiological data and surveillance systems that strengthens our ability to monitor the spread of healthcare-associated infections and antibiotic resistance across the continent.
COMBACTE-MAGNET performs pharmaceutical trials of two potential new treatments:
- MEDI3902, a bispecific monoclonal antibody that inhibits two key virulence factors of Pseudomonas aeruginosa, PcrV and Psl. It has shown promising activity against P. aeruginosa in laboratory and animal studies, and has already undergone Phase I safety testing in adult humans. The consortium will carry out Phase II and Phase III studies in adult ICU patients to learn more about the antibody’s safety, its optimal dosing, and its efficacy in ICU patients;
- AIC499, potentially a new and potent member of the family of beta-lactam antibiotics. Given alone or in combination with a beta-lactamase inhibiting drug (BLI), AIC499 has shown strong activity against a broad range of multidrug-resistant strains of P. aeruginosa and Acinetobacter, both in laboratory and animal studies. AIC499 is being developed by the German-based biotechnology firm AiCuris. COMBACTE-MAGNET carries out Phase I and Phase II trials to assess the safety and the efficacy of AIC499.
Management Board Members COMBACTE-MAGNET
Project Management Officers COMBACTE-MAGNET